US 12,312,416 B2
Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
Michael C. Jensen, Bainbridge Island, WA (US); and James F. Matthaei, Seattle, WA (US)
Assigned to Seattle Children's Hospital, Seattle, WA (US)
Appl. No. 16/965,859
Filed by Seattle Children's Hospital, Seattle, WA (US)
PCT Filed Jan. 17, 2019, PCT No. PCT/US2019/014054
§ 371(c)(1), (2) Date Jul. 29, 2020,
PCT Pub. No. WO2019/156795, PCT Pub. Date Aug. 15, 2019.
Claims priority of provisional application 62/627,147, filed on Feb. 6, 2018.
Prior Publication US 2020/0354477 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/725 (2006.01); A61P 35/00 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/44 (2013.01) [C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C07K 2317/53 (2013.01); C07K 2319/33 (2013.01)] 18 Claims
 
1. A method of treating or inhibiting a solid tumor in a subject in need thereof, wherein the subject's bloodstream comprises engineered T cells comprising a chimeric antigen receptor (CAR), wherein the CAR specifically binds fluorescein, the method comprising:
administering to the subject a composition comprising fluorescein conjugated to a phospholipid ether (FL-PLE) in an amount effective to label tumor cells in the solid tumor,
wherein the T cells comprising the CAR that specifically bind the fluorescein and kill tumor cells in the solid tumor, thereby treating or inhibiting the solid tumor.